Summary

  • Earric Lee spearheads heat-therapy standards-setting before conclusive randomized evidence exists, keying the field’s credibility to multisite trials that are not yet funded.
  • Jari Laukkanen described the funding constraint: pharmaceutical companies run such trials, but the research community lacks the resources.
  • Ashley Mason reported that inconsistent terms block data pooling — “We’re all over the place” — and that consistent vocabulary is the prerequisite for the field to be taken seriously.
  • Ant Shepherd attributed the field’s strongest signal to Finnish observational associations that experts stress rely on self-reports and can be skewed by other factors.
  • The Norwegian Sauna Society, the host resort The Well, and the Sauna Research Foundation — a nonprofit backed by a Minnesota-based longevity entrepreneur and other private funders — financed the organizing meeting, concentrating near-term capital in wellness-adjacent sources.

The inaugural International Heat Therapy Research Symposium, held outside Oslo, Norway, in late September, brought together about 15 scientists to organize the study of heat therapy — a category that includes Finnish sauna, infrared, hot water immersion and more — and its immediate output, by the organizers’ account, is a vocabulary and a trial agenda, not a finding. The standards effort, spearheaded by Earric Lee, a postdoctoral researcher at the Montreal Heart Institute, is meant to turn what has been a niche and disparate area of research into a credible scientific field: as Ashley Mason, a clinical psychologist at the University of California, San Francisco, put it, “We want to introduce this as an actual field of research, not something fringy, or woo-woo.” The enterprise carries two independent constraints that can each sink it. The standards-setting and large randomized trials the organizers describe as prerequisites for any recommendation will take years, while the observational findings that created the field are already circulating at consumer speed. And the capital required to close the evidence gap has no obvious commercial owner, so the field can fail at the funding gate before it fails at the knowledge gate. The organizing question raised by the meeting is therefore not whether the field can agree on terminology, but what the field’s structure can absorb as it scales — across its evidence base, its funding, and its proximity to a commercial wellness market, each of which carries a distinct failure profile.

The field’s two constraints

Chronological. The standards-setting and large randomized trials that the organizers describe as prerequisites for any recommendation will take years, while the observational findings that created the field are already circulating at consumer speed. Lee put the gap bluntly: “People want information. I know ‘listen to your body’ doesn’t cut it,” and “I really can’t give you recommendations, and that’s the honest truth of it.”

Allocative. The capital required to close the evidence gap has no obvious commercial owner, so the enterprise can fail at the allocation gate — trials never launch, or never finish — before it ever fails at the knowledge gate. A perfectly specified multisite protocol with no payer is still an unrun trial. Jari Laukkanen of the University of Eastern Finland named the resource gap directly: “Pharmaceutical companies are doing this kind of study, but they have the resources. We don’t have those yet.” Ant Shepherd, a professor of clinical environmental physiology at the University of Portsmouth, described the same gate from the payer side: “The governments aren’t going to listen until we put the hardcore, randomized-control trials in front of them.”

Who benefits, who pays, who is exposed

The intervention under study is heat exposure: inexpensive, non-patentable, delivered through infrastructure that does not map onto an existing reimbursement pathway. That, in the reporting’s account, is why no large commercial constituency has an obvious incentive to fund the confirmation. Shepherd framed the therapeutic proposition around access rather than substitution: “Exercise is king, exercise is medicine, but for those who can’t do that easily, can we get some of the same effects?” — “It looks like we can.” That identifies a genuinely valuable population — people who cannot easily exercise, the elderly, cardiovascular and metabolic patients — and, simultaneously, the absence of a payer.

Public funding exists where heat practices are deeply interwoven into society. In Finland and Japan, public money has supported some of this research, and in the U.S., the National Institutes of Health funds Mason’s mental-health work. Lee said the newly formed group hopes to secure funding from public agencies in Europe. Laukkanen described such studies as “really demanding.” The reporting indicates that the kind of expensive, large-scale trials scientists envision may largely rely on foundations and private funders. The symposium itself was funded by the Norwegian Sauna Society, the resort where it took place, The Well, and the Sauna Research Foundation, a nonprofit backed by a Minnesota-based longevity entrepreneur and several other private funders.

Beneficiary-side concentration mirrors the funding concentration: the field’s strongest signal originates with Laukkanen’s University of Eastern Finland group, where Lee earned his Ph.D., and the named U.S. trials run through Mason — key-person dependency layered on funder concentration. On the commercial side, benefit concentrates on branded equipment: a specific infrared machine, a particular hot-tub protocol, each marketable independently of the class-level question the Oslo group is trying to answer.

What happens next

The immediate deliverable is standardization. Organizers say the field needs consistent terms and larger multisite trials before heat therapy can be recommended for preventing or treating health conditions. How heat therapy is defined, and how environmental humidity and body temperature are measured, determines whether data from different countries and institutions can be pooled at all. “We’re all over the place,” Mason said. “If we want to be taken seriously, we need to have consistent terms, so that people understand how to refer to and talk about our work.” Lee described the standards process — “a painstaking process involving dozens of other experts” — as what will “set the stage for larger, multisite trials.” The reinforcing branch runs: standardization raises the probability that a large trial is interpretable, which raises the probability of guideline consideration, which is the only route to clinical adoption.

The interim period runs in parallel. Physicians will face patient questions before guidelines exist; the default advice — “listen to your body” — is one Lee said “doesn’t cut it.” Commercial markets for infrared saunas and hot tubs will absorb interim findings on their own translation timetables, without the researchers’ hedging discipline. And a counteracting branch needs no coordination to outpace the reinforcing one: the 40%-to-60% association between four-to-seven-times-weekly sauna use and lower risk of cardiovascular disease and death, relative to once-weekly use, derives from Finnish observational work that experts quoted in the reporting stress “relies on self-reports and can be skewed by other factors.” Shepherd said of that signal: “The effects are quite large, so we’re fairly optimistic, but that’s about as far we can go as scientists.” A caveat that travels at the speed of a scientific caveat cannot, in the interim, intercept a percentage that travels at the speed of a headline — which makes the association the most portable object the field has produced. The reporting does not specify the endpoint composition of the 40%-to-60% range; the underlying study text would resolve it.

What the flagship trials will adjudicate. Three evidentiary threads stand out: replication of the Finnish findings; extension of Shepherd’s lab’s hot-tub results — improved resting metabolic rate and some measures of insulin sensitivity for people with Type 2 diabetes; and the infrared-machine depression signal, built on a landmark single-session result. Lee’s randomized work — a trial showing that adding sauna to an exercise regime conferred added benefits for people at risk of cardiovascular disease, and a cardiac-rehabilitation trial now underway — is the leading indicator on the field’s central exposure.

The structural consequence of organizing. The effort itself raises expectations. Each public milestone of field-formation sharpens the question the flagship trials must answer; a null or mixed result would arrive to an audience that has been told, honestly, that no recommendations exist yet — a position that sets no ceiling on public inference. Over the long run the field forks: heat therapy either becomes a prescribed adjunct for patients who cannot exercise, or the field absorbs a failed-replication reset. The definitions the group settles on will circulate beyond the lab: terms chosen for trial comparability can become commercial and regulatory classifications.

How this is being framed

The meeting was held at The Well, a resort outside Oslo where nude bathing is the norm and essential-oil-infused rituals based on traditions such as the German Aufguss are held throughout the day, convened on the eve of the International Sauna Congress, an event that draws hundreds of sauna lovers and experts every four years. The venue itself markets the rituals under study. Organizers acknowledged the tension: the meeting was framed as an attempt to dispel what some acknowledged is “a whiff of wellness hype” — even as the field depends on sustained attention through the painstaking, multi-expert process Lee described. The anti-framing project is aimed at a moving target.

Public interest is described in the reporting as having surprised even long-time devotees, from social sauna meetups to “the broader wellness and optimization movement.” Hans Hägglund, a hematologist and stem-cell researcher at the Karolinska University Hospital in Stockholm, said: “It’s really booming.” “Unfortunately, there is still not very much evidence out there.”

Legibility is a double edge. As the field becomes an organized, named target — for regulators, skeptics, and media cycles — a single overclaimed finding anywhere in the wellness-adjacent space can damage the enterprise as a whole, even though no single component fails. The social contexts that give the practice its meaning — nude bathing, ritual, meetup culture — will largely be excluded from the intervention variables under standardization: a narrowing that is scientifically necessary and sociologically costly.

The scientific interest has deep roots — British scientists in the late 1700s ran experiments on thermoregulation — and the acute physiological response to extreme heat is now well understood: blood vessels dilate, heart rate speeds up, blood is pushed to the skin and cooled as the body sweats, and the body releases hormones and activates heat shock proteins that protect cells. That understanding has shaped medical care for heat-related illness. What has received considerably less attention from modern science is the therapeutic potential of heat exposure — the gap the symposium is organized around.

Where the structure is exposed

Within the fragility framework formalized by Nassim Taleb and Raphael Douady in the journal Quantitative Finance — which classifies a system whose losses grow faster than its stressors as fragile regardless of its average performance — the observational literature is the convex element: cheap to produce, it created the option value that fifteen scientists and a research agenda now exist to exercise, and its cost if wrong is bounded for the researchers who produced it. The concealed concave element is the public-facing claim surface built on that literature — and, with it, the capital base financing the verification. Its gains are small and frequent: each new associational study extends the runway, and each new sauna resort, meetup, and longevity venture deepens the pool of private money the field depends on.

The reported enthusiasm is not merely a load on the credibility firewall; it is the near-term funding channel. A well-powered randomized trial that returns null would not merely fail to confirm — it would attach the wellness-hype label the gathering is trying to dispel to the entire organizing effort at once, including the parts that are methodologically sound, in front of the very constituency whose private money — the resort, the sauna society, the longevity-backed foundation — is the field’s current substitute for the public funding it does not yet have. Credibility and capital are the same node, so the exposure is not additive but concentrated.

The field is leveraged on a small number of observational estimates with unusually large effect sizes. Routine criticism of self-report data is absorbed; a single large stressor — a failed reproduction of the Finnish association, or an adverse-event signal in the elderly and cardiac-rehabilitation populations the researchers explicitly prioritize — would impose a disproportionate loss on the field as a whole. The evidence portfolio approximates a barbell: well-understood acute physiology of heat stress on the safe pole, expensive therapeutic trials on the risky pole, and a vulnerable middle occupied by the many small underpowered studies Shepherd described as “lots and lots of lovely little studies.” Vacating that middle is the field’s structural task.

The Lindy pattern — associated with Benoit Mandelbrot and popularized by Nassim Taleb — cuts both ways here: the practices are old and culturally interwoven in Finland and Japan, but the evidentiary program is young, and the durability of the practice does not insure the evidence base.

The account also carries stress points the organizers did not name. The acute physiology of heat stress is well enough understood to have shaped medical care for heat-related illness, so public-health agencies could act on adverse-event reports before therapeutic trials conclude. Clinicians who recommend a modality that lacks guideline cover carry liability exposure, and equipment manufacturers will be held to claims made in the same evidentiary vacuum. The terms attached to wellness-adjacent private support are not described in the account; the possibility that foundation money carries outcome or timeline preferences is a live risk the reporting leaves open rather than establishes. Lee’s randomized results — not the standards process — are the first signal showing which way the cascade is running.

Failure scenarios and leading indicators

The pre-mortem protocol described by Gary Klein in the Harvard Business Review (September 2007) treats a future failure as a fact and works backward to its causes. Under that protocol, the standards initiative does not fail at consensus; it fails at the seam between the pace of its own verification and the pace of the claims built on its pre-verification literature. The component that yields is the interim-period firewall — the mechanism that does not exist by which an observational association with acknowledged self-report and confounding limits is kept from acquiring the status of a recommendation before the trials that would test it report. The load is an accumulation, and the load and the load-bearing structure are the same object: continued public uptake, continued translation of “associated with” into advice, and a funding model in which the entities financing the large trials are expressions of the same enthusiasm the trials must eventually adjudicate. When the trial reports, the market that paid for the test is also the market the test implicates.

The failure load concentrates in five places, each visible in the reporting. Load: a single failed flagship trial, or a safety signal in a frail population, exceeds what the field can currently absorb. Dependency: the evidence pyramid rests on the University of Eastern Finland cohort, a handful of named investigators, and foundation funding whose largest named source is a private nonprofit. Interface: the weakest joints are the measurement standards between controlled exposure and real-world practice — humidity, duration, ritual — and the translation boundary between research and the market. State: the accumulation of small positive findings raises the expectation threshold, and the fact that the symposium was convened partly to dispel what some acknowledged is “a whiff of wellness hype” suggests the state is already elevated. Emergent: the field’s new legibility as an organized target means damage can arrive without any single component failing.

Three breakage narratives follow from the structure.

A failed flagship trial. A decade out, a large multisite randomized trial returns null, or a safety signal appears in cardiac-rehabilitation or elderly participants; because credibility is concentrated, the loss cascades through funding and the field’s positioning. The chain traces to standardizing terms before multi-year funding is secured, to reliance on foundation money that may carry outcome or timeline preferences, and to outcome-measure selection. Early warnings include recruitment shortfalls, interim analyses, and funding gaps between trial phases; mitigations available now include pre-registration of outcomes, independent data monitoring, diversification of public funders, and explicit commitments to publish null results.

A misappropriation cascade. The market translates interim findings into product claims faster than the field can correct them; a regulator or a plaintiff’s attorney responds; the research enterprise absorbs responsibility for claims it did not make. The chain traces to holding the founding meeting at a venue that markets the rituals under study, and to accepting support from wellness-adjacent funders whose terms are not described in the account. Warnings include advertising claims citing the symposium, and complaints to advertising regulators; the consistent terms Mason calls for could govern how findings are described outside the lab as well as within it.

Stasis. The standards process takes the painstaking years Lee describes, public funding never arrives, and the field remains in the small-study regime while public interest curdles. The chain traces to sequencing decisions — treating standards work as a precondition for fundraising rather than running it in parallel with pilot multisite grants — and to treating foundation support as the bridge rather than the destination.

All of the leading indicators are visible in advance, and in this reporting: growth in citation of the Finnish figures without their caveats attached; proliferation of non-comparable protocols, the thing the standards process exists to eliminate; the gap between the number of “lovely little studies” and the number of adequately powered randomized ones; any slippage in the pipeline of publicly funded trials, signaling that the allocation gate closed before the knowledge gate opened; and advertising claims citing the symposium. The recovery path is the path the Oslo group has already embarked on: pre-specified terminology, common measurement, registered large trials, and published null results treated as outputs rather than embarrassments. The missed step the record would show is deliberate, on-the-record management of the interval: naming in advance what a null trial would and would not overturn, and separating — structurally, in the funding and disclosure record rather than rhetorically — the money that builds the field’s visibility from the money that tests its claims, while the field still controls its own vocabulary.

What the organizers can subtract

The field’s credibility is most exposed where a branded modality stands in for the class. The landmark single-session depression result came from a special infrared machine; Shepherd’s Type 2 diabetes findings came from hot-tub immersion. Each is a legitimate experiment, and each is also a marketable object separable from the class-level question. The constraint the organizers face is that every controlled result cited in the reporting is device- or protocol-anchored, while the class-level evidence is exclusively observational: the standards process is being asked to define a class before class-level randomized evidence exists, and its only rigorous test-beds are the devices themselves.

Consequently, the vocabulary may have to be built on physiological dose parameters — heat load, time, humidity, core-temperature response — precisely because those parameters generalize across devices. Organizing the vocabulary around the stimulus rather than the device is the subtraction most within the group’s control. It is also a subtraction the field may not be able to afford to make visible too early: de-emphasizing the branded trials would de-emphasize the only saleable evidence currently sustaining both the research agenda and its financing.

The organizers’ first public move is already subtractive in this sense: removing the association with “something fringy, or woo-woo,” in Mason’s words, rather than adding claims. The decisive variables are mostly external — the results of the first large trials, the posture of regulators, and the translation discipline of the market surrounding the practice. The standard the organizers have set for themselves — consistent terms, controlled trials, hedged claims — is the standard to which the field will be held, regardless of who provides the evidence.

Attribution and verification notes

The phrase “a whiff of wellness hype” is carried as what “some acknowledged” per the reporting; it is not attributed to Mason or to any organizer collectively. Mason’s own quoted language is verbatim: “We want to introduce this as an actual field of research, not something fringy, or woo-woo,” “We’re all over the place,” and “If we want to be taken seriously, we need to have consistent terms, so that people understand how to refer to and talk about our work.” The self-report and confounding limitation is attributed to the experts quoted in the reporting; Shepherd’s name is attached only to his verbatim quote: “The effects are quite large, so we’re fairly optimistic, but that’s about as far we can go as scientists.”

The 40%-to-60% figure is carried as an association, with the once-weekly comparator explicit, from Finnish observational work built on self-reports. Its direction is consistent with a published analysis by Laukkanen and colleagues (JAMA Internal Medicine 175(4):542-548, 2015) reporting hazard ratios for fatal cardiovascular disease and all-cause mortality approximately consistent with the range; the range’s endpoint composition is not specified in the reporting, and the underlying study text would resolve it. Independent verification of the underlying Finnish studies was not available to this analysis.

Framework vocabulary is carried under attribution: the fragility formalism of Nassim Taleb and Raphael Douady (Quantitative Finance; the working paper circulated in 2012); the pre-mortem protocol described by Gary Klein in the Harvard Business Review (September 2007); and the Lindy pattern, associated with Benoit Mandelbrot and popularized by Nassim Taleb, the coinage attributed to Goldman in 1964. The characterization of a system whose losses grow faster than its stressors, and the barbell analogy applied to an evidence portfolio, are approximations of the cited frameworks and have not been independently reviewed.

Analytical techniques used in this piece

This analysis applies the methods below. Each links to a short, plain-English explainer you can read and reuse.

Consequences & Sequels
Plays a decision forward to its first- and second-order consequences.
Fragility / Antifragility Audit
Asks whether a system gains or loses from volatility, shocks, and disorder (Taleb).
Pre-Mortem (Fragility)
Imagines a system has already broken and traces the structural fragilities that let it.